Hereditary Testing Market

Hereditary Testing Market by Disease Types (Hereditary Cancer Testing [Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer, and Others] and Hereditary Non-cancer Testing [Genetic Tests {Cardiac Diseases, Rare Diseases, and Others}, Newborn Genetic Screening, Preimplantation Genetic Diagnosis & Screening, and Non-invasive Prenatal Testing & Carrier Screening Tests]) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-819
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 135
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global hereditary testing market size was valued at USD 6.25 billion in 2020 and is projected to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growth of reproductive genetic health sector.

Hereditary testing, also simply known as genetic testing, refers to a type of laboratory testing that examines and analyzes a blood sample or any swab sample to identify genetic differences linked to hereditary or genetic disorder. This testing is widely used to determine if a person is at high risk for a genetic disorder that runs in their family such as hereditary cancer syndromes or neurological disorder. This genetic testing can be conducted at any stage of life, from pregnancy to adulthood. There are several types of genetic testing and no single genetic test that can detect all types of genetic disorders. Different genetic testing is done that is unique to patient, depending on patient’s medical and family history, as well as the kind of ailment. The genetic testing can be classified into single gene testing, panel testing, and Large-scale genetic or genomic testing. Large-scale genetic or genomic testing is further bifurcated into exome sequencing and genome testing. Doctors prescribe exome and genome sequencing for patients with complicated medical histories. Genomic testing on a large scale is also utilized in research to understand more about the genetic origins of diseases. Large-scale genetic tests can provide results that have nothing to do with why the test was requested in the first place.

Genetic testing, in general, pose no physical danger. Blood and cheek swab testing are almost risk-free. A genetic test may or may not yield useful information on the gene in issue in various situations. Everyone's genes are different and these differences do not always have an impact on your health. However, distinguishing between a disease-causing gene and a harmless gene variant might be challenging at times. Variants of uncertain significance are the term given to these changes. Follow-up testing or periodic assessments of the gene throughout time may be required in these cases.

Global Hereditary Testing Market Summary

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing demand newborn testing is projected to boost the market growth during the forecast period.
  • Growing demand for better tools to predict, diagnose, treat, and monitor illness are expected to drive the market growth during the forecast period.
  • Increasing advancements in distribution models by technology suppliers are projected to propel the market growth during the coming years.
  • Benefits associated with tests and improved healthcare outcomes are expected to drive the market growth during the forecast period.
  • Cost and security possess as key challenges that can hamper the market growth during the forecast period.
  • Lack of adequate testing regulations is projected to hamper the market growth in the coming years.
  • Increased emphasis on R&D investment and technological advancements are expected to offer lucrative opportunities for the market players.

Scope of the Report

The report on the global hereditary testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Hereditary Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Disease Types (Hereditary Cancer Testing [Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Stomach/Gastric Cancer, Melanoma, Sarcoma, Uterine Cancer, Pancreatic Cancer, and Others] and Hereditary Non-cancer Testing [Genetic Tests {Cardiac Diseases, Rare Diseases, and Others}, Newborn Genetic Screening, Preimplantation Genetic Diagnosis & Screening, and Non-invasive Prenatal Testing & Carrier Screening Tests])

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Inc.; CooperSurgical, Inc.; Agilent Technologies, Inc.; and Thermo Fisher Scientific, Inc.

 

Global Hereditary Testing Market Segment Insights

Hereditary cancer testing segment is likely to dominate the market
Based on disease types, the global hereditary testing market is bifurcated into hereditary cancer testing and hereditary non-cancer testing. The hereditary cancer testing is further divided into lung cancer, breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, uterine cancer, pancreatic cancer, and others. While the hereditary non-cancer testing segment is further segmented into genetic tests, newborn genetic screening, preimplantation genetic diagnosis & screening, and non-invasive prenatal testing (NIPT) & carrier screening tests. Meanwhile, the genetic tests segment is further sub-segmented into cardiac diseases, rare diseases, and others. The hereditary cancer testing segment is likely to dominate the market in the coming years owing to rising number of cancer cases globally and rapid development of new technology for cancer diagnostic devices

On the other hand, the Lung cancer segment is anticipated to expand at a rapid pace during the forecast period as majority of lung cancer are not related to inherited genetic mutations. Similarly, the Human Papillomavirus (HPV) causes most cervical cancer cases, rather than genetic alterations. Furthermore, lack of adequate evidence on cervical cancer heredity is expected to boost the research activities in this segment.

Global Hereditary Testing Market By Disease Type

Europe is expected to hold a key share of the market
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Europe is expected to hold a key share of the global hereditary testing market with a large revenue share during the forecast period. The growth of the segment is attributed to presence of key players that are providing innovative and effective genetic tests, the widespread use of advanced treatments, and government recommendations to ensure the quality of hereditary testing services.

On the other hand, the market in Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to rising awareness and improvements in healthcare facilities. Furthermore, increasing demand newborn testing in the region is also expected to drive the market growth in this region.

Global Hereditary Testing Market By Region

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hereditary Testing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Hereditary Testing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Hereditary Testing Market - Supply Chain
  4.5. Global Hereditary Testing Market Forecast
     4.5.1. Hereditary Testing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Hereditary Testing Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Hereditary Testing Market Absolute $ Opportunity
5. Global Hereditary Testing Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Hereditary Testing Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Hereditary Testing Demand Share Forecast, 2019-2026
6. North America Hereditary Testing Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Hereditary Testing Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Hereditary Testing Demand Share Forecast, 2019-2026
7. Latin America Hereditary Testing Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Hereditary Testing Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Hereditary Testing Demand Share Forecast, 2019-2026
8. Europe Hereditary Testing Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Hereditary Testing Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Hereditary Testing Demand Share Forecast, 2019-2026
9. Asia Pacific Hereditary Testing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Hereditary Testing Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Hereditary Testing Demand Share Forecast, 2019-2026
10. Middle East & Africa Hereditary Testing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Hereditary Testing Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Hereditary Testing Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Hereditary Testing Market: Market Share Analysis
  11.2. Hereditary Testing Distributors and Customers
  11.3. Hereditary Testing Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Myriad Genetics, Inc.
     11.4.2. Invitae Corporation;
     11.4.3. Illumina, Inc.
     11.4.4. Natera, Inc.
     11.4.5. Laboratory Corporation of America Holdings
     11.4.6. F. Hoffmann-La Roche Ltd
     11.4.7. Quest Diagnostics Inc.
     11.4.8. Co
Segments Covered in the Report
The global hereditary testing market has been segmented on the basis of

Disease Types
  • Hereditary Cancer Testing
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Cervical Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Stomach/Gastric Cancer
    • Melanoma
    • Sarcoma
    • Uterine Cancer
    • Pancreatic Cancer
    • Others
  • Hereditary Non-cancer Testing
    • Genetic Tests
      • Cardiac Diseases
      • Rare Diseases
      • Others
    • Newborn Genetic Screening
    • Preimplantation Genetic Diagnosis & Screening
    • Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests
Regions
  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa
Key Players
  • Myriad Genetics, Inc.
  • Invitae Corporation;
  • Illumina, Inc.
  • Natera, Inc.
  • Laboratory Corporation of America Holdings
  • F. Hoffmann-La Roche Ltd
  • Quest Diagnostics Inc.
  • CooperSurgical, Inc.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.

Some of the major players competing in the global hereditary testing market are Myriad Genetics, Inc.; Invitae Corporation; Illumina, Inc.; Natera, Inc.; Laboratory Corporation of America Holdings; F. Hoffmann-La Roche Ltd; Quest Diagnostics Inc.; CooperSurgical, Inc.; Agilent Technologies, Inc.; and Thermo Fisher Scientific, Inc.

Some of the key business strategies employed by companies includes mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For example, in September 2019, Blueprint Genetics, a Finnish firm, patenered with ARCHIMEDlife, a rare disease diagnostics firm, to provide biochemical testing for rare disorders in North America. Both companies intended to expand their genetic illness testing services through this collaboration in order to better serve their consumers.

Global Hereditary Testing Market By Key Players

Buy Report